Literature DB >> 27113204

Time course study of microglial and behavioral alterations induced by 6-hydroxydopamine in rats.

Thiago Pereira da Silva1, Anicleto Poli2, Daniela Balz Hara2, Reinaldo Naoto Takahashi2.   

Abstract

Understanding the mechanisms responsible for nonmotor manifestations of Parkinson's disease (PD) is crucial in the search for new therapeutic approaches. The aim of the present study was to evaluate the time course of behavioral, neurochemical, and microglial responses after a retrograde partial lesion of the nigrostriatal pathway induced by bilateral injection of 6-hydroxydopamine (6-OHDA). The results showed that 6-OHDA was able to produce both anhedonic and anxiety behaviors; however, an increase of microglial density in some brain areas (substantia nigra, hippocampus and striatum) and deficits in locomotor activity was observed only one week after the lesion. Striatal levels of dopamine (DA) and dihydroxyphenylacetic acid (DOPAC) were reduced by approximately 60% at all times tested. Conversely, increased levels of serotonin (5-HT) and its metabolite were also noted in the striatum only at the first week. These data extend our previous findings and suggest that the retrograde and partial damage of dopaminergic neurons in the substantia nigra can induce effects resembling premotor symptoms of PD, two and three weeks after injury.
Copyright © 2016 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  6-Hydroxydopamine; Dopaminergic neurons; Neuroinflammation; Parkinson's disease

Mesh:

Substances:

Year:  2016        PMID: 27113204     DOI: 10.1016/j.neulet.2016.04.049

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  7 in total

1.  Docosahexaenoic acid protects motor function and increases dopamine synthesis in a rat model of Parkinson's disease via mechanisms associated with increased protein kinase activity in the striatum.

Authors:  Neha Milind Chitre; Bo Jarrett Wood; Azizi Ray; Nader H Moniri; Kevin Sean Murnane
Journal:  Neuropharmacology       Date:  2020-01-27       Impact factor: 5.250

Review 2.  Application of Neurotoxin-Induced Animal Models in the Study of Parkinson's Disease-Related Depression: Profile and Proposal.

Authors:  Ya-Kui Mou; Li-Na Guan; Xiao-Yan Yao; Jia-Hui Wang; Xiao-Yu Song; Yong-Qiang Ji; Chao Ren; Shi-Zhuang Wei
Journal:  Front Aging Neurosci       Date:  2022-05-13       Impact factor: 5.702

3.  Long-Term Motor Cortical Electrical Stimulation Ameliorates 6-Hydroxydopamine-Induced Motor Dysfunctions and Exerts Neuroprotective Effects in a Rat Model of Parkinson's Disease.

Authors:  Chi-Wei Kuo; Ming-Yuan Chang; Ming-Yi Chou; Chien-Yuan Pan; Chih-Wei Peng; Hui-Chiun Tseng; Tsu-Yi Jen; Xiao-Kuo He; Hui-Hua Liu; Thi Xuan Dieu Nguyen; Pi-Kai Chang; Tsung-Hsun Hsieh
Journal:  Front Aging Neurosci       Date:  2022-02-16       Impact factor: 5.750

Review 4.  Recent advances in the pathology of prodromal non-motor symptoms olfactory deficit and depression in Parkinson's disease: clues to early diagnosis and effective treatment.

Authors:  Yeojin Bang; Juhee Lim; Hyun Jin Choi
Journal:  Arch Pharm Res       Date:  2021-06-19       Impact factor: 4.946

Review 5.  Depression in Parkinson's Disease: The Contribution from Animal Studies.

Authors:  Jéssica Lopes Fontoura; Camila Baptista; Flávia de Brito Pedroso; José Augusto Pochapski; Edmar Miyoshi; Marcelo Machado Ferro
Journal:  Parkinsons Dis       Date:  2017-10-11

Review 6.  Neuropsychiatric Disorders in Parkinson's Disease: What Do We Know About the Role of Dopaminergic and Non-dopaminergic Systems?

Authors:  Kathy Dujardin; Véronique Sgambato
Journal:  Front Neurosci       Date:  2020-01-29       Impact factor: 4.677

7.  Antidepressant-Like Properties of Intrastriatal Botulinum Neurotoxin-A Injection in a Unilateral 6-OHDA Rat Model of Parkinson's Disease.

Authors:  Veronica Antipova; Carsten Holzmann; Alexander Hawlitschka; Martin Witt; Andreas Wree
Journal:  Toxins (Basel)       Date:  2021-07-20       Impact factor: 4.546

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.